Clinical Trial Update: Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety, tolerability, and PK/PD of LCZ696 in patients with stable heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure | Phase 2 | Status: COMPLETED